Definium Therapeutics Gains FDA Breakthrough Therapy Designation for DT120 in MDD
NEW YORK — September 8, 2026 Definium Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK — September 8, 2026 Definium Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
HYOGO, Japan, June 8, 2026 JCR Pharmaceuticals Co., Ltd. announced new clinical findings from its J-Brain Cargo® blood-brain barrier...
